LEBANON, Ind. – Eli Lilly and Company will invest an additional $4.5 billion in Boone County to create a new center for advanced manufacturing and drug development. The Lilly Medicine Foundry will allow the drugmaker to research new ways of producing medicine and scale up production of pharmaceuticals for clinical trials. The company described the facility as the first of its kind, combining research and manufacturing at a single site. It will be located in Indiana's LEAP Research and Innovation District in Lebanon. With the announcement, Lilly will have invested more than $13 billion into the area. Once fully operational, the Medicine Foundry will add 400 full-time jobs for engineers, scientists, operations personnel and lab technicians. Image via Eli Lilly and Company "As we accelerate our work to discover new medicines for the toughest diseases, we're continuing to invest in state-of-the-art infrastructure to support our growing pipeline," said David A. Ricks, Lilly's chair and CEO. "In addition to supplying high-quality medicine for our clinical studies, this new complex will further strengthen our process development and scale up our manufacturing capabilities to speed delivery of next-generation medicines to patients around the world. The state will provide support for Lilly, including infrastructure improvements for roads, electricity and other utilities. Incentives are also tied to the company’s investment and employment goals. "Lilly's continued investment in Indiana solidifies our state's role as a hub for cutting-edge science and technology," said Gov. Eric Holcomb. "For nearly 150 years, Lilly has been committed to growing its roots and reach in Indiana, cultivating local talent, and driving scientific advancements that benefit patients around the world. I couldn't be more excited about the opportunities Lilly's Medicine Foundry will bring to communities throughout our great state." The Medicine Foundry is expected to open in late 2027. It’s the fourth major investment in Lebanon announced by the company since May 2022.